New drug combo aims to keep aggressive blood cancer at bay after second transplant
NCT ID NCT03030261
Summary
This study tests whether a three-drug combination (elotuzumab, pomalidomide, and dexamethasone) given as ongoing maintenance therapy can help people with multiple myeloma that has returned after their first stem cell transplant. The treatment is given after participants receive a second stem cell transplant, with the goal of keeping the cancer in remission longer and preventing another relapse. Researchers will measure how long patients live without their cancer getting worse and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorado Blood Cancer Institute (Sarah Cannon)
Denver, Colorado, 80218, United States
-
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.